147 related articles for article (PubMed ID: 9192926)
21. Effect of nebulizer type and antibiotic concentration on device performance.
Weber A; Morlin G; Cohen M; Williams-Warren J; Ramsey B; Smith A
Pediatr Pulmonol; 1997 Apr; 23(4):249-60. PubMed ID: 9141110
[TBL] [Abstract][Full Text] [Related]
22. [Effect of rhDNase on the respiratory function and nutritional status of children and adolescents with mucoviscidosis].
Wizla-Derambure N; Michaud L; Sardet A; Deschildre A; Loeuille GA; Tassin E; Loire N; Buisine C; Boutry E; Dias J; Hecquet F; Turck D
Arch Pediatr; 1998 Apr; 5(4):378-83. PubMed ID: 9759156
[TBL] [Abstract][Full Text] [Related]
23. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.
Wilmott RW; Amin RS; Colin AA; DeVault A; Dozor AJ; Eigen H; Johnson C; Lester LA; McCoy K; McKean LP; Moss R; Nash ML; Jue CP; Regelmann W; Stokes DC; Fuchs HJ
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1914-7. PubMed ID: 8665055
[TBL] [Abstract][Full Text] [Related]
24. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer.
Standaert TA; Vandevanter D; Ramsey BW; Vasiljev M; Nardella P; Gmur D; Bredl C; Murphy A; Montgomery AB
J Aerosol Med; 2000; 13(2):147-53. PubMed ID: 11010595
[TBL] [Abstract][Full Text] [Related]
25. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
[TBL] [Abstract][Full Text] [Related]
26. Nebulizer delivery of tobramycin to the lower respiratory tract.
Weber A; Smith A; Williams-Warren J; Ramsey B; Covert DS
Pediatr Pulmonol; 1994 May; 17(5):331-9. PubMed ID: 8058428
[TBL] [Abstract][Full Text] [Related]
27. Multicenter, open-label study of recombinant human DNase in cystic fibrosis patients with moderate lung disease. DNase International Study Group.
Harms HK; Matouk E; Tournier G; von der Hardt H; Weller PH; Romano L; Heijerman HG; FitzGerald MX; Richard D; Strandvik B; Kolbe J; Kraemer R; Michalsen H
Pediatr Pulmonol; 1998 Sep; 26(3):155-61. PubMed ID: 9773909
[TBL] [Abstract][Full Text] [Related]
28. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial.
Minasian C; Wallis C; Metcalfe C; Bush A
Thorax; 2010 Jan; 65(1):51-6. PubMed ID: 19996349
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers.
Coates AL; MacNeish CF; Lands LC; Meisner D; Kelemen S; Vadas EB
Chest; 1998 Apr; 113(4):951-6. PubMed ID: 9554630
[TBL] [Abstract][Full Text] [Related]
30. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
32. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?
van der Giessen LJ; Gosselink R; Hop WC; Tiddens HA
Eur Respir J; 2007 Oct; 30(4):763-8. PubMed ID: 17596273
[TBL] [Abstract][Full Text] [Related]
34. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis.
Suri R; Metcalfe C; Wallis C; Bush A
Pediatr Pulmonol; 2004 Apr; 37(4):305-10. PubMed ID: 15022126
[TBL] [Abstract][Full Text] [Related]
35. Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis.
Conway SP; Watson A
Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S64-8. PubMed ID: 9155855
[No Abstract] [Full Text] [Related]
36. Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.
Shah PL; Scott SF; Fuchs HJ; Geddes DM; Hodson ME
Thorax; 1995 Apr; 50(4):333-8. PubMed ID: 7785003
[TBL] [Abstract][Full Text] [Related]
37. The timing of rhDNase in relation to airway clearance therapy-unplugged.
Tannenbaum EL; Ranganathan S
Pediatr Pulmonol; 2007 Dec; 42(12):1235; author reply 1236-7. PubMed ID: 17708574
[No Abstract] [Full Text] [Related]
38. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.
Ramsey BW; Astley SJ; Aitken ML; Burke W; Colin AA; Dorkin HL; Eisenberg JD; Gibson RL; Harwood IR; Schidlow DV
Am Rev Respir Dis; 1993 Jul; 148(1):145-51. PubMed ID: 8317790
[TBL] [Abstract][Full Text] [Related]
40. Nebulised bronchodilators, antibiotics and rhDNase for children with cystic fibrosis.
Spencer DA
Thorax; 1997 Apr; 52 Suppl 2(Suppl 2):S89-91. PubMed ID: 9155860
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
